List of Therapeutic Companies in Ireland - 37

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. For more information, visit www.amarincorp.com. See our Community Guidelines: bit.ly/2L7xEW6

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

We are a biopharmaceutical company passionately committed to providing solutions for overlooked and unmet medical needs through patient-focused, innovative products.

Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients.

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Celtic Biotech is developing novel candidate therapies for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to increase survival, improve quality-of-life and reduce treatment costs for cancer patients. Celtic Biotech is focusing its research on solid tumours, including non-small-cell lung cancer (NSCLC), as its initial targets. The Company's lead candidate, CB24 (Crotoxin), has been observed to be highly toxic to various tumour cell lines in pre-clinical and early clinical studies.

Consilient Health is a pharmaceutical company with a rich heritage of commercialising medicines in areas including women’s health, urology and endocrinology. Established in 2005, Consilient Health is headquartered in Ireland with offices in the UK and Sweden (for the Nordic region) We have formed strong partnerships in Benelux and Spain and continue to expand our geographic footprint in Europe. As an independent, privately-held and profitable business with a strong balance sheet, we can make decisions quickly and are able to invest in long-term collaborations and partnerships to expand our portfolio of products and to support our partners’ objectives. Our goal is to address patients’ and healthcare professionals’ unmet needs with medicines that are differentiated and we are actively seeking to in-license late stage developments or marketed products. We do not undertake research and development and are not a manufacturer. Consilient Health deliver everything from regulatory affairs through to market access, supply chain, distribution, medical affairs, marketing and sales all underpinned by quality and compliance. Our focus is on driving value in our partners’ brands, maximizing their commercial potential, enabling them to expand their geographical footprint and providing access for patients. For more information please visit www.consilienthealth.com CORP-CH-204(2) Date of preparation July 2022

Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy. Our clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases and Colon Infections. Our effort is aimed to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection rate of pre-cancerous lesions during colonoscopy. Along with our presence in drugs manufacturing, we have significant innovative research and operations supporting our growing portfolio of specialty products. Learn more at www.cosmopharma.com/.

What We Do CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics. The most crucial issue of intracellular delivery for large molecules, especially for gene therapy, remains the cellular membrane. This biological barrier is a double-edged sword; while it prevents infectious agents from entering our body and causing disease, it also stands between the successful use of life-saving medicines and advanced therapeutic technologies. The successful delivery of therapeutics into target cells and organelles would minimize the undesired ‘off target' side effects and reduce the required dose. Why We Do Our founder's father was diagnosed with cancer when she was still a student. She witnessed her father suffering from the side effects of his therapy over years. This life experience defined the goal of her life 'how to make cancer drugs safer and better' to make an impact in oncology and do her bit in the global fight against cancer. CyGenica is the result of her and our team's intense desire to make significant contributions to alleviate this suffering and improve the quality of life of millions of cancer patients. Who We Are We are a team of ambitious academicians and professionals striving to improve patient outcomes worldwide. Our goal is to develop the world's safest molecular carrier for therapeutics delivery and grow as an authentic market leader in enabling the next generation genome editing therapeutics for various life-threatening diseases such as cancer. With an indomitable spirit, we are committed to improve the quality of life of such patients.

DS Biopharma was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life for people with diseases for which current therapies are unsatisfactory. Our vision is to enhance people's dignity and well-being by developing these products through a careful balance of applied pharmacology and clinical science.

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering. Juvenescence has a broad pipeline in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span.

Keltic Pharma is based in a world leading laboratory in Glasgow with our highly skilled team of industrial scientists and leading academics. We work alongside commercial partners and universities to deploy novel innovative technologies in the pursuit of next generation drugs for unmet clinical needs.

Loci Orthopaedics develops innovative orthopaedics medical technologies to meet large unmet clinical needs.

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation. We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control of their own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle. Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'​.

Omnispirant is a biotechnology company that develops a novel platform technology using inhaled stem cell exosomes for treating respiratory diseases.

OncoAssure is a medical diagnostics company that identifies, develops, and commercialises clinically important biomarkers to significantly improve cancer management and treatment. We aim to help clinicians provide the right treatment to the right patient at the right time.

ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.

Orbsen Therapeutics Limited aims to become a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. We are developing a novel proprietary technology that permits the isolation of pure and defined stomal cells from human tissue and a range of other species. The multi-species elements allow our technology to move seamlessly from the research laboratories to the clinic. The technology is designed to ensure that resulting therapies comply with the forthcoming stringent EMA and UK BSI guidelines regarding the purity and definition of cellular therapies. We believe that our technology will set the standard for regenerative medicine into the future. Orbsen Therapeutics was originally formed in 2006 as a spin out company from REMEDI, Ireland's Regenerative Medicine Institute in NUI Galway. Founded and led by some of the leading scientists in the field of regenerative medicine we operate from within the Orbsen Building, on campus at NUI Galway, which houses REMEDI's state of the art research facilities. The company has already participated in EU FP7 funded research progammes and has a significant research pipeline coming to fruition over the coming years.

Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women’s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire. The Society for Women’s Health Research estimates that about one in ten premenopausal women suffer from HSDD, making it one of the most common female sexual problems.

Developing innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times.

PLANTeDIT uses genome editing tools such as CRISPR/Cas9 RNPs® to create genome edited plants.

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.

Relevium Medical are a biopharmaceutical company with locations in Ireland and the US. We aspire to improve the lives of people with debilitating chronic pain conditions through creating superior treatments.

Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).

At Shorla Oncology we develop and commercialize innovative oncology drugs for women's and pediatric cancers. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla's world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.

SOMAÍ Pharmaceuticals is a leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio. At SOMAÍ, we are building a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics. We envision a world where people live a healthy lifestyle empowered by natural cannabis medicine. SOMAÍ owns a state-of-the-art manufacturing facility and indoor cultivation in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.

Our team at Starling Surgical is working to develop a new revolution in wound closure technology. The Quickstitch is the only device that provides all the clinical advantages of meticulously tied sutures, at the speed of a skin stapler. Our goal is to disrupt the industry of wound closure by delivering a device that provides an optimum wound closure every-time. The device is so intuitive to operate, that users have been delighted by its simplicity. Whether it is a long arduous coronary artery bypass or a short quick mole removal, the only part the patient sees, is the scar. We want to make sure your patients see a beautiful scar after every operation. Our team has developed, tested, iterated and developed and tested some more, to give you the best device for wound closure. Our goal is to get the QuickStitch into the hands of users, so they can see the amazing results for themselves.

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Uniphar is a diversified healthcare services organisation with activities in Ireland, UK, Europe, the USA and APAC.